Pericarditis Market

The prevalence of cardiovascular diseases is found to be increasing over the last decade. This is attributed to the rising incidences of chronic diseases such as obesity and diabetes, which are major risk factors for cardiovascular diseases such as pericarditis, heart attack, and hypertension. As per the American Heart Association, nearly 92.1 million Americans were diagnosed with cardiovascular diseases in 2017. Additionally, it also stated that the prevalence is found to be higher in men than in women.

Furthermore, in the same year, more than 92% of the patients exhibited major symptoms of heart diseases such as chest pain, heartburns, and

strokes

Recently, the prevalence of cardiovascular diseases is found to be increasing from the last few years. The American Heart Association stated that in 2015, 3.7% of the Asian population was diagnosed with chronic heart disease, while 21% of the people had hypertension.

Cardiovascular disease is one of the significant chronic disease responsible for a high death toll across the globe. This emphasizes the need for the development of new diagnostics and treatment devices around the world. The market is also affected by the increasing number of people diagnosed with these diseases at an early stage. Therefore, the prevalence of cardiovascular disease would drive the growth of the market during the forecast period.

The pericarditis drugs market is driven by the increasing number of patients suffering from cardiovascular diseases, thus signifying the need for the development of new technologically advanced devices for monitoring the heart rate. Continuous monitoring of cardiovascular diseases is an important aspect of cardiology. Therefore, the prevalence of pericarditis is increasing with a rise in the prevalence of cardiovascular diseases, fueling market growth.

Global Pericarditis Market Segmentation

The global pericarditis market has been segmented into type, application, and end user. 

Based on type, the global pericarditis drugs market has been segmented acute pericarditis, recurrent pericarditis, and chronic pericarditis.

Based on diagnosis & treatment, the global market has been divided into diagnosis and treatment. The diagnosis segment is further divided into electrocardiogram (ECG), echocardiogram, computerized tomography (CT), X-Ray. The treatment segment is bifurcated into medication (non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine) and surgical treatment.

Based on end user, the global market has been segmented into hospitals & clinics and medical institutes & research laboratories. The hospitals & clinics segment accounted for a market value of USD 840.30 million in 2017.

Global Pericarditis Market Key Players

The prominent players in the global pericarditis market are: 

Pfizer Inc. AstraZeneca Plc Novartis International AG Allergan plc. Merck & Co., Inc.  Bayer AG Reckitt Benckiser Group Plc. PerkinElmer, Inc. FUJIFILM Holdings Corporation Sanofi and Johnson & Johnson Services, Inc

Some of the key strategies followed by the players operating in the global pericarditis market are innovation, product development, acquisition, and expansion.

Global Pericarditis Market Regional Analysis

The global pericarditis market, based on region, is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas is estimated to dominate the global pericarditis drugs market during the forecast period. This is attributed to the rising investments in research and development owing to investments in reputed research centers and government institutions and increasing expenditure on healthcare play a vital role in the growth of the regional market. Besides, several research grants are given by governmental agencies.

The European market for pericarditis is expected to be the second-largest during the forecast period. The presence of medical device companies, the rising burden of rheumatoid arthritis (RA), and growing healthcare spending are expected to boost the growth of the market in this region. Additionally, the companies operating in the market are mainly focusing on mergers and acquisition, which is expected to support market growth.

Asia-Pacific is estimated to be the fastest-growing market due to the growing geriatric population, rapid developments in technology. In addition to this, improving healthcare infrastructure has increased the number of research activities in the region. Moreover, in the region, China accounted for a market share of 24.6% in 2017.

Furthermore, the market in the Middle East & Africa is expected to witness slow growth due to limited access to healthcare facilities.

Key Updates In July 2017, Pfizer Inc. extended the collaboration with Catalent, Inc., a global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products for the development and manufacture of Advil Liqui-Gels. In October 2018, Reckitt Benckiser (RB) launched a 24-hour pain relief patch along with a campaign to educate patients about pain to encourage patients to facilitate pain management. In October 2018, FUJIFILM Medical Systems USA, Inc., a provider of diagnostic imaging and medical informatics solutions launched the FCT Embrace wide bore computed tomography (CT) imaging unit in the US, thereby entering into the US computed tomography market.

Market Segmentation

Global Pericarditis Market, by Type

Acute Pericarditis Recurrent Pericarditis Chronic Pericarditis

Global Pericarditis Market, by Diagnosis & Treatment

Diagnosis Electrocardiogram (ECG), Echocardiogram, Computerized Tomography (CT) X-Ray Treatment Medication Surgical Treatment

Global Pericarditis Market, by End User

Hospitals & Clinics Medical Institutes & Research laboratories

Global Pericarditis Market, by Region

AmericasNorth America US Canada Latin America EuropeWestern Europe Germany UK France Italy Spain Rest of Western Europe Eastern Europe Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific Middle East & Africa Middle East Africa Available Additional Customizations Pricing Analysis Competitive Benchmarking for Global Pericarditis Market Intended Audience Medical device manufacturers and distributors Government research organizations Hospitals and clinics Regulatory agencies Pharmaceutical companies

The development of novel therapeutic agents for pericarditis is reshaping the Global Global Pericarditis Market Industry. Recent advancements in pharmacotherapy, including biologics and targeted therapies, offer new avenues for treatment, particularly for patients with recurrent or chronic pericarditis. These emerging options are designed to improve efficacy and reduce side effects compared to traditional treatments. As clinical trials yield promising results, the market is poised for expansion, with stakeholders keen to capitalize on these innovations. The anticipated growth trajectory suggests a market value of 7.16 USD Billion by 2035, reflecting the potential impact of these therapeutic advancements.

The increasing prevalence of pericarditis globally is a primary driver for the Global Global Pericarditis Market Industry. Factors such as autoimmune diseases, infections, and post-surgical complications contribute to this rise. For instance, studies indicate that pericarditis affects approximately 27 per 100,000 individuals annually, with higher rates observed in specific demographics. This growing patient population necessitates enhanced diagnostic and therapeutic options, thereby expanding market opportunities. As the market is projected to reach 3.74 USD Billion in 2024, addressing this rising incidence is crucial for stakeholders in the Global Global Pericarditis Market Industry.

Growing awareness about pericarditis among healthcare professionals and the general public is driving the Global Global Pericarditis Market Industry. Educational initiatives and campaigns aimed at recognizing symptoms and understanding treatment options are essential for early diagnosis and management. This heightened awareness leads to increased patient consultations and demand for medical interventions. Furthermore, as healthcare systems prioritize patient education, the market is expected to benefit from a more informed patient base. This trend aligns with the projected compound annual growth rate of 6.09% from 2025 to 2035, indicating a robust future for the industry.

Technological innovations in diagnostic tools are significantly influencing the Global Global Pericarditis Market Industry. Enhanced imaging techniques, such as echocardiography and MRI, allow for more accurate and timely diagnosis of pericarditis. These advancements facilitate early intervention, which is essential for improving patient outcomes. Moreover, the integration of artificial intelligence in diagnostic processes is expected to streamline workflows and reduce diagnostic errors. As these technologies become more widely adopted, they are likely to contribute to the market's growth, with projections indicating a market value of 7.16 USD Billion by 2035.

The expansion of healthcare infrastructure globally is a significant factor propelling the Global Global Pericarditis Market Industry. Governments and private entities are investing in healthcare facilities and services, particularly in developing regions. This investment enhances access to medical care, including specialized treatments for pericarditis. Improved healthcare infrastructure facilitates better patient management and follow-up care, which is crucial for chronic conditions like pericarditis. As healthcare systems evolve, the market is likely to experience growth, supported by the increasing availability of resources and services tailored to pericarditis management.